BioCryst Pharmaceuticals BCRX Effective Income Tax Rate Reconciliation Tax Credits Research
Effective Income Tax Rate Reconciliation Tax Credits Research at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's effective income tax rate reconciliation tax credits research.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's effective income tax rate reconciliation tax credits research?
- BioCryst Pharmaceuticals (BCRX) reported effective income tax rate reconciliation tax credits research of 0% in Q4 2025.
- What does effective income tax rate reconciliation tax credits research mean?
- Represents the total tax benefit derived from research and development tax credits applied to the effective tax rate reconciliation. It quantifies the extent to which R&D spending lowers the company's tax liability compared to the statutory rate.